S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.17%) $78.03
Gas
(5.50%) $2.15
Gold
(0.06%) $2 311.10
Silver
(-0.13%) $26.80
Platinum
(0.22%) $964.75
USD/EUR
(-0.36%) $0.929
USD/NOK
(-1.16%) $10.86
USD/GBP
(-0.13%) $0.797
USD/RUB
(0.35%) $91.45

リアルタイムの更新: Kaken Pharmaceutical Co., [4521.T]

取引所: JPX セクター: Healthcare 産業: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-07)

Expected move: +/- 0.00%

最終更新日時2 5月 2024 @ 15:15

0.03% ¥ 3 478.00

Live Chart Being Loaded With Signals

Commentary (2 5月 2024 @ 15:15):

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation...

Stats
本日の出来高 108 100
平均出来高 124 575
時価総額 131.71B
EPS ¥0 ( 2024-02-05 )
次の収益日 ( ¥0 ) 2024-05-07
Last Dividend ¥75.00 ( 2023-03-30 )
Next Dividend ¥0 ( N/A )
P/E 44.25
ATR14 ¥1.086 (0.03%)

ボリューム 相関

長: -0.07 (neutral)
短: -0.70 (moderate negative)
Signal:(42.479) Neutral

Kaken Pharmaceutical Co., 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kaken Pharmaceutical Co., 相関 - 通貨/商品

The country flag 0.61
( weak )
The country flag 0.24
( neutral )
The country flag -0.18
( neutral )
The country flag 0.68
( moderate )
The country flag -0.44
( neutral )
The country flag -0.82
( strong negative )

Kaken Pharmaceutical Co., 財務諸表

Annual 2022
収益: ¥72.98B
総利益: ¥39.56B (54.20 %)
EPS: ¥144.79
FY 2022
収益: ¥72.98B
総利益: ¥39.56B (54.20 %)
EPS: ¥144.79
FY 2022
収益: ¥76.03B
総利益: ¥41.58B (54.68 %)
EPS: ¥251.43
FY 2021
収益: ¥74.98B
総利益: ¥40.91B (54.56 %)
EPS: ¥347.37

Financial Reports:

No articles found.

Kaken Pharmaceutical Co., Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥75.00
(N/A)
¥0
(N/A)
¥75.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

Kaken Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 2.36 - Decrease likely (52.76%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥7.50 2001-03-27
Last Dividend ¥75.00 2023-03-30
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 46 --
Total Paid Out ¥1 874.70 --
Avg. Dividend % Per Year 0.00% --
Score 3.32 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 2.36
Div. Directional Score 6.18 --
Next Divdend (Est)
(2024-07-03)
¥0 Estimate 1.26 %
Dividend Stability
0.10 Bad
Dividend Score
3.32
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
8214.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
7595.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
6788.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
6135.T Ex Dividend Junior 2023-09-28 Annually 0 0.00%
4837.T Ex Dividend Junior 2024-03-28 Sporadic 0 0.00%
4045.T Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
3271.T Ex Dividend Junior 2024-06-27 Sporadic 0 0.00%
2294.T Ex Dividend Junior 2024-04-26 Annually 0 0.00%
9147.T Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
7999.T Ex Dividend Junior 2023-09-28 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.04111.5009.1810.00[0 - 0.5]
returnOnAssetsTTM0.01761.2009.4110.00[0 - 0.3]
returnOnEquityTTM0.02141.500-0.873-1.310[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM5.640.80010.008.00[1 - 3]
quickRatioTTM4.640.80010.008.00[0.8 - 2.5]
cashRatioTTM2.631.50010.0010.00[0.2 - 2]
debtRatioTTM0.0229-1.5009.62-10.00[0 - 0.6]
interestCoverageTTM248.721.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM145.292.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM145.292.0010.0010.00[0 - 20]
debtEquityRatioTTM0.0275-1.5009.89-10.00[0 - 2.5]
grossProfitMarginTTM0.5391.0004.354.35[0.2 - 0.8]
operatingProfitMarginTTM0.06211.000-0.758-0.758[0.1 - 0.6]
cashFlowToDebtRatioTTM1.4291.0003.173.17[0.2 - 2]
assetTurnoverTTM0.4280.800-0.478-0.382[0.5 - 2]
Total Score10.01

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM44.411.0005.620[1 - 100]
returnOnEquityTTM0.02142.50-0.561-1.310[0.1 - 1.5]
freeCashFlowPerShareTTM145.292.0010.0010.00[0 - 30]
dividendYielPercentageTTM4.311.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM145.292.0010.0010.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.0471.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.07631.000-0.5920[0.1 - 0.5]
Total Score2.36

Kaken Pharmaceutical Co.,

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。